ACHC Stock Analysis: Acadia Healthcare | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 2.641m USD | 12M Return: 29.5% | US00404A1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.5M
EPS Trend: -89.1%
Qual. Beats: 0
Rev. Trend: 98.7%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a U.S.-based behavioral healthcare services provider that owns and operates a diversified network of facilities, including acute inpatient psychiatric hospitals, residential recovery and eating disorder treatment centers, comprehensive treatment centers, residential treatment centers, and outpatient behavioral health programs. Founded in 2005 and headquartered in Franklin, Tennessee, the company serves communities across the United States and Puerto Rico, operating under a capital-intensive, facility-based business model typical of the healthcare facilities sub-industry, which is subject to extensive state and federal licensing and reimbursement regulations.
- Patient admission recovery drives same-store revenue growth
- Labor cost inflation pressures operating margins
- New facility openings accelerate revenue expansion
| Net Income: -1.13b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 4.59 > 1.0 |
| NWC/Revenue: 9.14% < 20% (prev 5.20%; Δ 3.94% < -1%) |
| CFO/TA 0.04 > 3% & CFO 210.5m > Net Income -1.13b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.4m) vs 12m ago 1.04% < -2% |
| Gross Margin: 35.56% > 18% (prev 81.24%; Δ -45.67% > 0.5%) |
| Asset Turnover: 56.82% > 50% (prev 51.20%; Δ 5.62% > 0%) |
| Interest Coverage Ratio: -5.82 > 6 (EBIT TTM -879.6m / Interest Expense TTM 151.1m) |
| A: 0.06 (Total Current Assets 845.3m - Total Current Liabilities 537.6m) / Total Assets 5.55b |
| B: -0.14 (Retained Earnings -750.8m / Total Assets 5.55b) |
| C: -0.15 (EBIT TTM -879.6m / Avg Total Assets 5.93b) |
| D: 0.59 (Book Value of Equity 1.98b / Total Liabilities 3.35b) |
| Altman-Z'' = -0.46 = B |
| DSRI: 1.10 (Receivables 555.5m/483.2m, Revenue 3.37b/3.23b) |
| GMI: 2.28 (GM 81.24% / 35.56%) |
| AQI: 0.69 (AQ_t 0.27 / AQ_t-1 0.39) |
| SGI: 1.04 (Revenue 3.37b / 3.23b) |
| TATA: -0.24 (NI -1.13b - CFO 210.5m) / TA 5.55b) |
| Beneish M = -1.96 (Cap -4..+1) = B |
As of September 24, 2026, the stock is trading at USD 28.51 with a total of 2,231,381 shares traded. Over the past week, the price has changed by +1.24%, over one month by -0.73%, over three months by +16.18% and over the past year by +29.47%.
Current recommended Stop Loss: 25.40 (which is 10.9% or 2.3 ATR below the current price).
Acadia Healthcare has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ACHC.
- StrongBuy: 7
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 33.6 | 17.7% |
P/E Forward = 15.1515
P/S = 0.7843
P/B = 1.3322
P/EG = 1.3745
Revenue TTM = 3.37b USD
EBIT TTM = -879.6m USD
EBITDA TTM = -683.6m USD
Long Term Debt = 2.38b USD (from longTermDebt, last quarter)
Short Term Debt = 53.3m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 150.7m
Net Debt = 2.54b USD (calculated: Debt 2.71b - CCE 171.3m)
Enterprise Value = 5.18b USD (2.64b + Debt 2.71b - CCE 171.3m)
Interest Coverage Ratio = -5.82 (Ebit TTM -879.6m / Interest Expense TTM 151.1m)
EV/FCF = -274.1x (Enterprise Value 5.18b / FCF TTM -18.9m)
FCF Yield = -0.36% (FCF TTM -18.9m / Enterprise Value 5.18b)
FCF Margin = -0.56% (FCF TTM -18.9m / Revenue TTM 3.37b)
Net Margin = -33.44% (Net Income TTM -1.13b / Revenue TTM 3.37b)
Gross Margin = 35.56% ((Revenue TTM 3.37b - Cost of Revenue TTM 2.17b) / Revenue TTM)
Gross Margin QoQ = 16.58% (prev 16.53%)
Tobins Q-Ratio = 0.93 (Enterprise Value 5.18b / Total Assets 5.55b)
Interest Expense / Debt = 5.56% (Interest Expense 151.1m / Debt 2.71b)
Taxrate = 44.29% (9.75m / 22.0m)
NOPAT = -490.0m (EBIT -879.6m * (1 - 44.29%)) [loss with tax shield]
Current Ratio = 1.57 (Total Current Assets 845.3m / Total Current Liabilities 537.6m)
Debt / Equity = 1.37 (Debt 2.71b / totalStockholderEquity, last quarter 1.98b)
Debt / EBITDA = -3.72 (negative EBITDA) (Net Debt 2.54b / EBITDA -683.6m)
Debt / FCF = -134.5 (out of range, set to none) (Net Debt 2.54b / FCF TTM -18.9m)
Total Stockholder Equity = 2.25b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.00% (Net Income -1.13b / Total Assets 5.55b)
RoE = -50.02% (Net Income TTM -1.13b / Total Stockholder Equity 2.25b)
RoCE = -18.98% (EBIT -879.6m / Capital Employed (Equity 2.25b + L.T.Debt 2.38b))
RoIC = -10.01% (negative operating profit) (NOPAT -490.0m / Invested Capital 4.89b)
WACC = 7.41% (E(2.64b)/V(5.36b) * Re(11.84%) + D(2.71b)/V(5.36b) * Rd(5.56%) * (1-Tc(0.44)))
Discount Rate = 11.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -70.54 | Cagr: -0.31%
[DCF] Fair Price = unknown (Cash Flow -18.9m)
EPS Correlation: -89.14 | EPS CAGR: -23.83% | SUE: 0.76 | # QB: 0
Revenue Correlation: 98.72 | Revenue CAGR: 6.05% | SUE: 1.83 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.47 | Chg30d=-1.22% | Revisions=-7% | Analysts=12
EPS current Year (2026-12-31): EPS=1.55 | Chg30d=+0.01% | Revisions=+46% | GrowthEPS=-22.4% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=1.82 | Chg30d=+0.13% | Revisions=+46% | GrowthEPS=+17.5% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +32% (up=21, down=10)